Size | Price | Stock | Qty |
---|---|---|---|
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
Mometasone Furoate (formerly Sch 32088; Sch32088; SCH-32088) is a potent glucocorticoid receptor agonist and an approved anti-inflammatory drug used as a topical formulation to reduce inflammation of the skin or in the airways. As a topical corticosteroid, mometasone furoate has anti-inflammatory, antipruritic, and vasoconstrictive properties.
ln Vitro |
Mometasone furoate attaches to a glucocorticoid receptor induces conformational changes in the receptor, separation from chaperones, and the receptor travels to the nucleus[1]. Mometasone furoate (0.1-10 μM; 2h before LPS stimulation) substantially suppresses LPS-stimulated nitrite generation in a concentration-dependent manner in J774 macrophages, The IC50 value is 0.00024 μM for Mometasone furoate in J774 cells[1]. Mometasone furoate (0.1-10 μM; 2h before LPS stimulation) is more powerful than DEX, it significantly reduces iNOS expression at a 0.01 µM dose whereas Dex became active at 0.1 µM. Additionally, the inhibition of cox-2 protein expression at 0.01 µM is 79% for Mometasone furoate and 39% for Dex[1].
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
[1]. Maria Galuppo, et al. Use of Mometasone furoate in prolonged treatment of experimental spinal cord injury in mice: A comparative study of three different glucocorticoids. Pharmacol Res. 2015 Sep;99:316-28
[2]. https://go.drugbank.com/drugs/DB14512 |
Molecular Formula |
C27H30CL2O6
|
|
---|---|---|
Molecular Weight |
521.43
|
|
CAS # |
83919-23-7
|
|
Related CAS # |
Mometasone furoate-d3
|
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
|
SMILES |
Cl[C@@]12[C@]3(C([H])=C([H])C(C([H])=C3C([H])([H])C([H])([H])[C@@]1([H])[C@]1([H])C([H])([H])[C@@]([H])(C([H])([H])[H])[C@](C(C([H])([H])Cl)=O)([C@@]1(C([H])([H])[H])C([H])([H])[C@]2([H])O[H])OC(C1=C([H])C([H])=C([H])O1)=O)=O)C([H])([H])[H]
|
|
InChi Key |
WOFMFGQZHJDGCX-ZULDAHANSA-N
|
|
InChi Code |
InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1
|
|
Chemical Name |
(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.79 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.79 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9178 mL | 9.5890 mL | 19.1780 mL | |
5 mM | 0.3836 mL | 1.9178 mL | 3.8356 mL | |
10 mM | 0.1918 mL | 0.9589 mL | 1.9178 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.